Tag:
Alcon
Latest Headlines
Latest Headlines
Minority Schering shareholders extract another €46 per share from Bayer
A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they said they deserved.
Novartis nabs EU clearance for Jetrea; Roche's hep C drug Pegasys wins new use
Novartis won European approval for its eye drug Jetrea, as a treatment for vitreomacular traction, and the European Medicines Agency also approved a new use for Roche's hepatitis C drug Pegasys.
FDA knocks Alcon for marketing updated cataract laser minus clearance
Alcon marketed its LenSx laser to treat cataracts without gaining proper regulatory clearance for updated software and other improvements to the product, the FDA alleges in a warning letter citing the company.
Novartis' Jimenez says no need to sell Roche stake
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Novartis faces probes on Tekturna tactics, Iran sales
Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.
Novartis unit buys SensoMotoric's eye surgery tech
Alcon, Novartis' eye-care unit, has bought German company SensoMotoric Instruments' opthalmic business, acquiring technology for cataract surgery.
Novartis grabs rights to eye drug in $494M deal
Belgian biotech ThromboGenics ( $ THR ) has picked up a major partnership with the Alcon unit of Swiss drug giant Novartis ( $NVS ) for its experimental therapeutic for an eye ailment known as symptomatic vitreomacular adhesion, or VMA. And the deal with Alcon, which grants rights to market the eye drug outside the U.S., could be worth up to €375 million ($494 million) to ThromboGenics.
Novartis eye unit subpoenaed in U.S. probe
Novartis ( $NVS ) has disclosed a U.S. government probe into alleged healthcare fraud at its newly acquired eyecare unit Alcon, Reuters reports. The company received a subpoena from HHS, requesting
Consolidating admin ops in Fort Worth, Alcon asks for tax break
When M&A integration takes away in one place, it sometimes gives somewhere else. Witness Alcon, which is asking the city of Fort Worth, TX, for some tax breaks on a planned expansion that's
Novartis aims to beat $1.9B in cost savings by year's end
Novartis ( $NVS ) has two things to say. It now expects more bang for its buck from Alcon. The eye-care acquisition, which cost Novartis $51 billion, will deliver high single-digit to low double-digit
